{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:00:53Z","timestamp":1789214453749,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270185"],"award-info":[{"award-number":["82270185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2021JJ10077"],"award-info":[{"award-number":["2021JJ10077"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a refractory hematologic malignancy that poses a serious threat to human health. Exploring alternative therapeutic strategies capable of inducing alternative modes of cell death, such as ferroptosis, holds great promise as a viable and effective intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed online database data and collected clinical samples to verify the expression and function of BMAL1 in AML. We conducted experiments on AML cell proliferation, cell cycle, ferroptosis, and chemotherapy resistance by overexpressing\/knocking down BMAL1 and using assays such as MDA detection and BODIPY 581\/591 C11 staining. We validated the transcriptional regulation of HMGB1 by BMAL1 through ChIP assay, luciferase assay, RNA level detection, and western blotting. Finally, we confirmed the results of our cell experiments at the animal level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BMAL1 up-regulation is an observed phenomenon in AML patients. Furthermore, there existed a strong correlation between elevated levels of BMAL1 expression and inferior prognosis in individuals with AML. We found that knocking down BMAL1 inhibited AML cell growth by blocking the cell cycle. Conversely, overexpressing BMAL1 promoted AML cell proliferation. Moreover, our research results revealed that BMAL1 inhibited ferroptosis in AML cells through BMAL1-HMGB1-GPX4 pathway. Finally, knocking down BMAL1 can enhance the efficacy of certain first-line cancer therapeutic drugs, including venetoclax, dasatinib, and sorafenib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our research results suggest that BMAL1 plays a crucial regulatory role in AML cell proliferation, drug resistance, and ferroptosis. BMAL1 could be a potential important therapeutic target for AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05753-y","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T07:01:33Z","timestamp":1714806093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway"],"prefix":"10.1007","volume":"150","author":[{"given":"Hong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Da","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"3","key":"5753_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ajh.26831","volume":"98","author":"A Al-Kali","year":"2023","unstructured":"Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, Litzow M (2023) A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. Am J Hematol 98(3):472\u2013480. https:\/\/doi.org\/10.1002\/ajh.26831","journal-title":"Am J Hematol"},{"issue":"4","key":"5753_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bbrc.2018.12.039","volume":"508","author":"Y Bai","year":"2019","unstructured":"Bai Y, Meng L, Han L, Jia Y, Zhao Y, Gao H, Kang R, Wang X, Tang D, Dai E (2019) Lipid storage and lipophagy regulates ferroptosis. Biochem Biophys Res Commun 508(4):997\u20131003. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.039","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"5753_CR3","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/cncr.30680","volume":"123","author":"G Battipaglia","year":"2017","unstructured":"Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A (2017) Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer 123(15):2867\u20132874. https:\/\/doi.org\/10.1002\/cncr.30680","journal-title":"Cancer"},{"issue":"7","key":"5753_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/jco.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Soci\u00e9 G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30(7):735\u2013741. https:\/\/doi.org\/10.1200\/jco.2011.36.9868","journal-title":"J Clin Oncol"},{"issue":"3","key":"5753_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3324\/haematol.2019.240747","volume":"106","author":"A Burchert","year":"2021","unstructured":"Burchert A (2021) Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica 106(3):664\u2013670. https:\/\/doi.org\/10.3324\/haematol.2019.240747","journal-title":"Haematologica"},{"key":"5753_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ebiom.2019.07.004","volume":"45","author":"E Burgermeister","year":"2019","unstructured":"Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, H\u00e4rtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP (2019) Aryl hydrocarbon receptor nuclear translocator-like (ARNTL\/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine 45:139\u2013154. https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.004","journal-title":"EBioMedicine"},{"issue":"1","key":"5753_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13046-022-02296-3","volume":"41","author":"JK Byun","year":"2022","unstructured":"Byun JK, Lee S, Kang GW, Lee YR, Park SY, Song IS, Yun JW, Lee J, Choi YK, Park KG (2022) Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. J Exp Clin Cancer Res 41(1):98. https:\/\/doi.org\/10.1186\/s13046-022-02296-3","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5753_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, H\u00fcttemann M, Taub JW, Ge Y (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther 5(1):288. https:\/\/doi.org\/10.1038\/s41392-020-00361-x","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5753_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021a) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 18(5):280\u2013296. https:\/\/doi.org\/10.1038\/s41571-020-00462-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"5753_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41418-020-00728-1","volume":"28","author":"X Chen","year":"2021","unstructured":"Chen X, Yu C, Kang R, Kroemer G, Tang D (2021b) Cellular degradation systems in ferroptosis. Cell Death Differ 28(4):1135\u20131148. https:\/\/doi.org\/10.1038\/s41418-020-00728-1","journal-title":"Cell Death Differ"},{"key":"5753_CR11","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2023.0007","author":"R Chen","year":"2023","unstructured":"Chen R, Zou J, Kang R, Tang D (2023a) The redox protein HMGB1 in cell death and cancer. Antioxid Redox Signal. https:\/\/doi.org\/10.1089\/ars.2023.0007","journal-title":"Antioxid Redox Signal"},{"issue":"7\u20139","key":"5753_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1089\/ars.2023.0236","volume":"39","author":"R Chen","year":"2023","unstructured":"Chen R, Zou J, Kang R, Tang D (2023b) The Redox Protein High-Mobility Group Box 1 in Cell Death and Cancer. Antioxid Redox Signal 39(7\u20139):569\u2013590. https:\/\/doi.org\/10.1089\/ars.2023.0236","journal-title":"Antioxid Redox Signal"},{"issue":"16","key":"5753_CR13","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120(16):3187\u20133205. https:\/\/doi.org\/10.1182\/blood-2012-03-362608","journal-title":"Blood"},{"issue":"4","key":"5753_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41418-018-0252-y","volume":"26","author":"D Denton","year":"2019","unstructured":"Denton D, Kumar S (2019) Autophagy-dependent cell death. Cell Death Differ 26(4):605\u2013616. https:\/\/doi.org\/10.1038\/s41418-018-0252-y","journal-title":"Cell Death Differ"},{"issue":"19","key":"5753_CR15","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/cncr.30140","volume":"122","author":"A Deol","year":"2016","unstructured":"Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W (2016) Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer 122(19):3005\u20133014. https:\/\/doi.org\/10.1002\/cncr.30140","journal-title":"Cancer"},{"key":"5753_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036","author":"P Dhakal","year":"2022","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR (2022) Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2022.101036","journal-title":"Blood Rev"},{"key":"5753_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR (2023) Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2022.101036","journal-title":"Blood Rev"},{"issue":"1","key":"5753_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL (2022) The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer 22(1):45\u201364. https:\/\/doi.org\/10.1038\/s41568-021-00407-4","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"5753_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","volume":"19","author":"I Dikic","year":"2018","unstructured":"Dikic I, Elazar Z (2018) Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol 19(6):349\u2013364. https:\/\/doi.org\/10.1038\/s41580-018-0003-4","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"5753_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"issue":"9","key":"5753_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B (2021) Towards precision medicine for AML. Nat Rev Clin Oncol 18(9):577\u2013590. https:\/\/doi.org\/10.1038\/s41571-021-00509-w","journal-title":"Nat Rev Clin Oncol"},{"key":"5753_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00648-1","author":"B Galy","year":"2023","unstructured":"Galy B, Conrad M, Muckenthaler M (2023) Mechanisms controlling cellular and systemic iron homeostasis. Nat Rev Mol Cell Biol. https:\/\/doi.org\/10.1038\/s41580-023-00648-1","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"5753_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X (2016) Ferroptosis is an autophagic cell death process. Cell Res 26(9):1021\u20131032. https:\/\/doi.org\/10.1038\/cr.2016.95","journal-title":"Cell Res"},{"issue":"12","key":"5753_CR24","doi-asserted-by":"publisher","first-page":"14351","DOI":"10.15252\/emmm.202114351","volume":"13","author":"R Gao","year":"2021","unstructured":"Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G, Tang F (2021) YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13(12):14351","journal-title":"EMBO Mol Med"},{"issue":"6","key":"5753_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T (2019) Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35(6):830\u2013849. https:\/\/doi.org\/10.1016\/j.ccell.2019.04.002","journal-title":"Cancer Cell"},{"issue":"8","key":"5753_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","volume":"12","author":"W Hou","year":"2016","unstructured":"Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, Kang R, Tang D (2016) Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12(8):1425\u20131428. https:\/\/doi.org\/10.1080\/15548627.2016.1187366","journal-title":"Autophagy"},{"issue":"1","key":"5753_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2022.0474","volume":"20","author":"C Huang","year":"2023","unstructured":"Huang C, Zhang C, Cao Y, Li J, Bi F (2023) Major roles of the circadian clock in cancer. Cancer Biol Med 20(1):1\u201324","journal-title":"Cancer Biol Med"},{"issue":"4","key":"5753_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282. https:\/\/doi.org\/10.1038\/s41580-020-00324-8","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"5753_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4161\/auto.6.8.13651","volume":"6","author":"R Kang","year":"2010","unstructured":"Kang R, Livesey KM, Zeh HJ, Loze MT, Tang D (2010) HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy 6(8):1209\u20131211. https:\/\/doi.org\/10.4161\/auto.6.8.13651","journal-title":"Autophagy"},{"issue":"3","key":"5753_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1586\/era.12.1","volume":"12","author":"GJ Kaspers","year":"2012","unstructured":"Kaspers GJ (2012) Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 12(3):405\u2013413. https:\/\/doi.org\/10.1586\/era.12.1","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"5753_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM (2017) Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia. Drugs 77(1):85\u201396. https:\/\/doi.org\/10.1007\/s40265-016-0677-x","journal-title":"Drugs"},{"key":"5753_CR32","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC (2016) Acute myeloid leukaemia. Nat Rev Dis Primers 2:16010. https:\/\/doi.org\/10.1038\/nrdp.2016.10","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"5753_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijantimicag.2016.06.012","volume":"48","author":"YW Lai","year":"2016","unstructured":"Lai YW, Campbell LT, Wilkins MR, Pang CN, Chen S, Carter DA (2016) Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus. Int J Antimicrob Agents 48(4):388\u2013394. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.012","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5753_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G (2020) Ferroptosis: past, present and future. Cell Death Dis 11(2):88. https:\/\/doi.org\/10.1038\/s41419-020-2298-2","journal-title":"Cell Death Dis"},{"issue":"51","key":"5753_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904197","volume":"31","author":"C Liang","year":"2019","unstructured":"Liang C, Zhang X, Yang M, Dong X (2019) Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater 31(51):e1904197. https:\/\/doi.org\/10.1002\/adma.201904197","journal-title":"Adv Mater"},{"issue":"15","key":"5753_CR36","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.7150\/ijbs.87964","volume":"19","author":"T Liu","year":"2023","unstructured":"Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, Guo J, Zhang B, Ma F, Wang Y, Peng L, Li P, Zhan Y (2023a) Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int J Biol Sci 19(15):5020\u20135035. https:\/\/doi.org\/10.7150\/ijbs.87964","journal-title":"Int J Biol Sci"},{"key":"5753_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188890","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W (2023b) GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188890","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"5753_CR38","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazi\u00e8re JC, Chauffert B, Galmiche A (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 133(7):1732\u20131742. https:\/\/doi.org\/10.1002\/ijc.28159","journal-title":"Int J Cancer"},{"key":"5753_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115849","author":"S Milnerowicz","year":"2023","unstructured":"Milnerowicz S, Maszewska J, Skowera P, Stelmach M, Lejman M (2023) AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242115849","journal-title":"Int J Mol Sci"},{"key":"5753_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2023.03.003","volume":"91","author":"C Miro","year":"2023","unstructured":"Miro C, Docimo A, Barrea L, Verde L, Cernea S, Sojat AS, Marina LV, Docimo G, Colao A, Dentice M, Muscogiuri G (2023) \u201cTime\u201d for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment. Semin Cancer Biol 91:99\u2013109. https:\/\/doi.org\/10.1016\/j.semcancer.2023.03.003","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"5753_CR41","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1177\/1078155218817816","volume":"25","author":"O Mustafa","year":"2019","unstructured":"Mustafa O, Abdalla K, AlAzmi AA, Elimam N, Abrar MB, Jastaniah W (2019) FLAG\/FLAG-IDA regimen for children with relapsed\/refractory acute leukemia in the era of targeted novel therapies. J Oncol Pharm Pract 25(8):1831\u20131838. https:\/\/doi.org\/10.1177\/1078155218817816","journal-title":"J Oncol Pharm Pract"},{"key":"5753_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112127","author":"L Pang","year":"2023","unstructured":"Pang L, Dunterman M, Xuan W, Gonzalez A, Lin Y, Hsu WH, Khan F, Hagan RS, Muller WA, Heimberger AB, Chen P (2023) Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2023.112127","journal-title":"Cell Rep"},{"issue":"1","key":"5753_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni E, Randi ML, Rosato A, Cagnin S (2023) Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res 42(1):259. https:\/\/doi.org\/10.1186\/s13046-023-02841-8","journal-title":"J Exp Clin Cancer Res"},{"key":"5753_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcp.2017.06.112","volume":"140","author":"L Probst","year":"2017","unstructured":"Probst L, D\u00e4chert J, Schenk B, Fulda S (2017) Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. Biochem Pharmacol 140:41\u201352. https:\/\/doi.org\/10.1016\/j.bcp.2017.06.112","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"5753_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cell.2016.03.015","volume":"165","author":"RV Puram","year":"2016","unstructured":"Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, J\u00e4r\u00e5s M, Chen MC, Li H, Tamayo A, Cowley GS, Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165(2):303\u2013316. https:\/\/doi.org\/10.1016\/j.cell.2016.03.015","journal-title":"Cell"},{"key":"5753_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104919","author":"Y Qiu","year":"2020","unstructured":"Qiu Y, Cao Y, Cao W, Jia Y, Lu N (2020) The Application of Ferroptosis in Diseases. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2020.104919","journal-title":"Pharmacol Res"},{"key":"5753_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214829120","author":"M Qu","year":"2023","unstructured":"Qu M, Zhang G, Qu H, Vu A, Wu R, Tsukamoto H, Jia Z, Huang W, Lenz HJ, Rich JN, Kay SA (2023) Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2214829120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5753_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tibs.2022.04.009","volume":"47","author":"ES Rasmussen","year":"2022","unstructured":"Rasmussen ES, Takahashi JS, Green CB (2022) Time to target the circadian clock for drug discovery. Trends Biochem Sci 47(9):745\u2013758. https:\/\/doi.org\/10.1016\/j.tibs.2022.04.009","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"5753_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10020-023-00717-3","volume":"29","author":"W Ren","year":"2023","unstructured":"Ren W, Zhao L, Sun Y, Wang X, Shi X (2023) HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. Mol Med 29(1):117. https:\/\/doi.org\/10.1186\/s10020-023-00717-3","journal-title":"Mol Med"},{"issue":"16","key":"5753_CR50","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/s1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Kr\u00e4mer A, Sch\u00e4fer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, H\u00e4nel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghan\u00df C, Repp R, Heits F, D\u00fcrk H, Hase J, Klut IM, Illmer T, Bornh\u00e4user M, Schaich M, Parmentier S, G\u00f6rner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16(16):1691\u20131699. https:\/\/doi.org\/10.1016\/s1470-2045(15)00362-9","journal-title":"Lancet Oncol"},{"key":"5753_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104725","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2020.104725","journal-title":"Pharmacol Res"},{"issue":"1","key":"5753_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","volume":"22","author":"T Sauerer","year":"2023","unstructured":"Sauerer T, Vel\u00e1zquez GF, Schmid C (2023) Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 22(1):180. https:\/\/doi.org\/10.1186\/s12943-023-01889-6","journal-title":"Mol Cancer"},{"issue":"23","key":"5753_CR53","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, L\u00fcbbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, G\u00f6tze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Sp\u00e4th D, Benner A, Krauter J, Ganser A, D\u00f6hner H, D\u00f6hner K (2014) Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124(23):3441\u20133449. https:\/\/doi.org\/10.1182\/blood-2014-05-578070","journal-title":"Blood"},{"issue":"1","key":"5753_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.v100.1.59","volume":"100","author":"S Schnittger","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, L\u00f6ffler H, Sauerland CM, Serve H, B\u00fcchner T, Haferlach T, Hiddemann W (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1):59\u201366. https:\/\/doi.org\/10.1182\/blood.v100.1.59","journal-title":"Blood"},{"issue":"4","key":"5753_CR55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.Cd-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N (2020) Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov 10(4):506\u2013525. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1011","journal-title":"Cancer Discov"},{"issue":"10","key":"5753_CR56","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram I, Bray F (2021) Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070. Nat Rev Clin Oncol 18(10):663\u2013672. https:\/\/doi.org\/10.1038\/s41571-021-00514-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"5753_CR57","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR (2022) Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185(14):2401\u20132421. https:\/\/doi.org\/10.1016\/j.cell.2022.06.003","journal-title":"Cell"},{"issue":"6","key":"5753_CR58","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"BR Stockwell","year":"2020","unstructured":"Stockwell BR, Jiang X, Gu W (2020) Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol 30(6):478\u2013490. https:\/\/doi.org\/10.1016\/j.tcb.2020.02.009","journal-title":"Trends Cell Biol"},{"key":"5753_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891","author":"GP Sullivan","year":"2022","unstructured":"Sullivan GP, Flanagan L, Rodrigues DA, T N C, (2022) The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abo6891","journal-title":"Sci Transl Med"},{"issue":"5","key":"5753_CR60","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1083\/jcb.200911078","volume":"190","author":"D Tang","year":"2010","unstructured":"Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, Lotze MT (2010) Endogenous HMGB1 regulates autophagy. J Cell Biol 190(5):881\u2013892. https:\/\/doi.org\/10.1083\/jcb.200911078","journal-title":"J Cell Biol"},{"issue":"2","key":"5753_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G (2021) Ferroptosis: molecular mechanisms and health implications. Cell Res 31(2):107\u2013125. https:\/\/doi.org\/10.1038\/s41422-020-00441-1","journal-title":"Cell Res"},{"issue":"12","key":"5753_CR62","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT (2023) The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol 23(12):824\u2013841. https:\/\/doi.org\/10.1038\/s41577-023-00894-6","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"5753_CR63","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.v99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U, Wermke M, Bornh\u00e4user M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326\u20134335. https:\/\/doi.org\/10.1182\/blood.v99.12.4326","journal-title":"Blood"},{"key":"5753_CR64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","volume":"152","author":"F Ursini","year":"2020","unstructured":"Ursini F, Maiorino M (2020) Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med 152:175\u2013185. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.027","journal-title":"Free Radic Biol Med"},{"key":"5753_CR65","unstructured":"Vakiti A (2023) Mewawalla P in StatPearls (StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC., Treasure Island (FL)"},{"issue":"7664","key":"5753_CR66","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL (2017) Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547(7664):453\u2013457. https:\/\/doi.org\/10.1038\/nature23007","journal-title":"Nature"},{"issue":"4","key":"5753_CR67","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2016.10.099","volume":"480","author":"D Wang","year":"2016","unstructured":"Wang D, Peng Y, Xie Y, Zhou B, Sun X, Kang R, Tang D (2016) Antiferroptotic activity of non-oxidative dopamine. Biochem Biophys Res Commun 480(4):602\u2013607. https:\/\/doi.org\/10.1016\/j.bbrc.2016.10.099","journal-title":"Biochem Biophys Res Commun"},{"key":"5753_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113527","author":"A Wang","year":"2022","unstructured":"Wang A, Fang M, Jiang H, Wang D, Zhang X, Tang B, Zhu X, Hu W, Liu X (2022) Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2022.113527","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5753_CR69","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10555-022-10072-0","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Guo H, He F (2023a) Circadian disruption: from mouse models to molecular mechanisms and cancer therapeutic targets. Cancer Metastasis Rev 42(1):297\u2013322. https:\/\/doi.org\/10.1007\/s10555-022-10072-0","journal-title":"Cancer Metastasis Rev"},{"key":"5753_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-023-01902-9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li H, He Q, Zou R, Cai J, Zhang L (2023b) Ferroptosis: underlying mechanisms and involvement in neurodegenerative diseases. Apoptosis. https:\/\/doi.org\/10.1007\/s10495-023-01902-9","journal-title":"Apoptosis"},{"key":"5753_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040891","author":"K Weaver","year":"2022","unstructured":"Weaver K, Skouta R (2022) The Selenoprotein Glutathione Peroxidase 4: From Molecular Mechanisms to Novel Therapeutic Opportunities. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10040891","journal-title":"Biomedicines"},{"issue":"10","key":"5753_CR72","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5(10):835\u2013844. https:\/\/doi.org\/10.1038\/nrd2130","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"5753_CR73","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1073\/pnas.1819728116","volume":"116","author":"Z Wu","year":"2019","unstructured":"Wu Z, Geng Y, Lu X, Shi Y, Wu G, Zhang M, Shan B, Pan H, Yuan J (2019) Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc Natl Acad Sci U S A 116(8):2996\u20133005. https:\/\/doi.org\/10.1073\/pnas.1819728116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5753_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2023.10.010","author":"Q Xiang","year":"2023","unstructured":"Xiang Q, Yi X, Zhu XH, Wei X, Jiang DS (2023) Regulated cell death in myocardial ischemia-reperfusion injury. Trends Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.tem.2023.10.010","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"5753_CR75","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","volume":"19","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kang R, Klionsky DJ, Tang D (2023) GPX4 in cell death, autophagy, and disease. Autophagy 19(10):2621\u20132638. https:\/\/doi.org\/10.1080\/15548627.2023.2218764","journal-title":"Autophagy"},{"key":"5753_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102564","author":"X Xu","year":"2023","unstructured":"Xu X, Li Y, Wu Y, Wang M, Lu Y, Fang Z, Wang H, Li Y (2023) Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2022.102564","journal-title":"Redox Biol"},{"issue":"6","key":"5753_CR77","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2326-6066.Cir-21-0559","volume":"10","author":"W Xuan","year":"2022","unstructured":"Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P (2022) Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res 10(6):770\u2013784. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0559","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"5753_CR78","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/ncb0910-814","volume":"12","author":"Z Yang","year":"2010","unstructured":"Yang Z, Klionsky DJ (2010) Eaten alive: a history of macroautophagy. Nat Cell Biol 12(9):814\u2013822. https:\/\/doi.org\/10.1038\/ncb0910-814","journal-title":"Nat Cell Biol"},{"issue":"1\u20132","key":"5753_CR79","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1\u20132):317\u2013331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010","journal-title":"Cell"},{"key":"5753_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw2238","author":"M Yang","year":"2019","unstructured":"Yang M, Chen P, Liu J, Zhu S, Kroemer G, Klionsky DJ, Lotze MT, Zeh HJ, Kang R, Tang D (2019) Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.aaw2238","journal-title":"Sci Adv"},{"issue":"4","key":"5753_CR81","first-page":"730","volume":"9","author":"F Ye","year":"2019","unstructured":"Ye F, Chai W, Xie M, Yang M, Yu Y, Cao L, Yang L (2019) HMGB1 regulates erastin-induced ferroptosis via RAS-JNK\/p38 signaling in HL-60\/NRAS(Q61L) cells. Am J Cancer Res 9(4):730\u2013739","journal-title":"Am J Cancer Res"},{"key":"5753_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.959738","author":"Z Yin","year":"2022","unstructured":"Yin Z, Li F, Zhou Q, Zhu J, Liu Z, Huang J, Shen H, Ou R, Zhu Y, Zhang Q, Liu S (2022) A ferroptosis-related gene signature and immune infiltration patterns predict the overall survival in acute myeloid leukemia patients. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2022.959738","journal-title":"Front Mol Biosci"},{"issue":"1","key":"5753_CR83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-020-00920-3","volume":"13","author":"S Yuan","year":"2020","unstructured":"Yuan S, Liu Z, Xu Z, Liu J, Zhang J (2020) High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies. J Hematol Oncol 13(1):91. https:\/\/doi.org\/10.1186\/s13045-020-00920-3","journal-title":"J Hematol Oncol"},{"issue":"28","key":"5753_CR84","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.2174\/092986712803341548","volume":"19","author":"G Zauli","year":"2012","unstructured":"Zauli G, Voltan R, Tisato V, Secchiero P (2012) State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem 19(28):4875\u20134884. https:\/\/doi.org\/10.2174\/092986712803341548","journal-title":"Curr Med Chem"},{"issue":"3","key":"5753_CR85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13402-022-00666-9","volume":"45","author":"L Zhang","year":"2022","unstructured":"Zhang L, Su X (2022) Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m(6)A demethylation of EIF4EBP1 and MLST8 mRNA. Cell Oncol (dordr) 45(3):355\u2013365. https:\/\/doi.org\/10.1007\/s13402-022-00666-9","journal-title":"Cell Oncol (dordr)"},{"issue":"3","key":"5753_CR86","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jnci\/djm328","volume":"100","author":"W Zhang","year":"2008","unstructured":"Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quint\u00e1s-Cardama A, Small D, Cortes J, Andreeff M (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3):184\u2013198. https:\/\/doi.org\/10.1093\/jnci\/djm328","journal-title":"J Natl Cancer Inst"},{"key":"5753_CR87","doi-asserted-by":"publisher","first-page":"1286718","DOI":"10.3389\/fphar.2023.1286718","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Sun J, Wang J, Meng T, Yang J, Zhou Y (2023) The role of ferroptosis in diabetic cardiovascular diseases and the intervention of active ingredients of traditional Chinese medicine. Front Pharmacol 14:1286718. https:\/\/doi.org\/10.3389\/fphar.2023.1286718","journal-title":"Front Pharmacol"},{"key":"5753_CR88","doi-asserted-by":"publisher","first-page":"1260839","DOI":"10.3389\/fimmu.2023.1260839","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H, Tang C, Wang M, Zhao H, Zhu Y (2023) Ferroptosis as an emerging target in rheumatoid arthritis. Front Immunol 14:1260839. https:\/\/doi.org\/10.3389\/fimmu.2023.1260839","journal-title":"Front Immunol"},{"key":"5753_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115118","author":"X Zheng","year":"2023","unstructured":"Zheng X, Lu J, Liu J, Zhou L, He Y (2023) HMGB family proteins: Potential biomarkers and mechanistic factors in cardiovascular diseases. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2023.115118","journal-title":"Biomed Pharmacother"},{"key":"5753_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111339","author":"JE Zhou","year":"2021","unstructured":"Zhou JE, Yu J, Wang Y, Wang H, Wang J, Wang Y, Yu L, Yan Z (2021) ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2021.111339","journal-title":"Biomed Pharmacother"},{"key":"5753_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176124","author":"W Zhu","year":"2023","unstructured":"Zhu W, Liu X, Yang L, He Q, Huang D, Tan X (2023) Ferroptosis and tumor immunity: In perspective of the major cell components in the tumor microenvironment. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176124","journal-title":"Eur J Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05753-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T23:21:38Z","timestamp":1717975298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5753"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05753-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3878236\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Xiangya Hospital, Central South University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"231"}}